Oncology Market Insights and Strategy
Evolving Challenges in the Oncology Market
Oncology is one of the fastest-growing areas of pharmaceutical and biopharmaceutical innovation. There is enthusiasm in many types of cancer studies, thanks to ongoing innovation and breakthroughs in advanced therapy options to help address diversity gaps, improved screening techniques and expanded clinical trial enrollment. Such advances are contributing to steady improvement in terms of both overall survival (OS) and progression-free survival (PFS) metrics within many forms of cancer.
With advancements reshaping the treatment landscape, there’s a unique set of challenges that come with adopting new technologies. Key challenges include:
- Accelerated approvals requiring the completion of post-marketing confirmatory studies with a positive outcome.
- New genomic testing and innovation in the treatment paradigm.
- Rapid changes in data create an information overload for treating physicians
New Article
Learn how to drive greater impact in your oncology product launch.
Read the latest article from EVERSANA’s experts Anne Marie Robertson, Suzanne Greenwood and Sneha Varma to view key considerations to bolster your commercial strategy and explore innovative approaches designed to meet modern market complexities.
READ NOWObstacles in Oncology Product Launches
Without the necessary internal resources and financing, today’s pharma/biopharma innovators are not able to carry out all the concurrent planning and strategic development, nor are they able to assume the risk on their own to ensure the successful commercialization of their lifesaving product.
Limited Resources
Lack of expertise and existing infrastructure hinder the ability to navigate the complexities of bringing a new therapy to market.
Risk
The risk associated with uncertain clinical endpoints and FDA approval, coupled with the need to quickly scale operations upon approval, poses significant financial hurdles and threats to a brand.
Engaging Providers
Engaging providers throughout the care continuum is necessary to ensure commercial success. The onus is on manufacturers to raise awareness of how the therapy works and how it will benefit patients, and to clearly articulate its overall value proposition – all while crafting a go-to-market strategy.
High Cost to Launch, Yet Low Success Rate
While the oncology drug pipeline is rapidly growing, stringent competition and an evolving provider environment are putting intense pressure on manufacturers to build effective commercialization infrastructures and launch products at unprecedented speeds, which comes at a steep price. Prepping for launch and the first five years of commercialization costs $265M on average and can range anywhere from $150M to $450M, yet 66% of drugs do not meet launch expectations. Both experienced and first-time launchers have to invest significantly in preparing for launch, with first-time launchers incurring additional investments to build up their infrastructure.
Next Gen Commercialization
Leveraging our award-winning model commercialization model, coupled with our deep bench of experts, EVERSANA partners with manufacturers to develop a customized, comprehensive go-to-market strategy agile enough to overcome any market challenge. Click here to learn more about EVERSANA ONCOLOGY™ Commercialization.
